Beur schreef op 12 april 2017 15:03:
Uit de notulen voor de AVA to be held at Holiday Inn Leiden, Haagse Schouwweg 10, 2332 KG Leiden, the Netherlands and organized by Pharming Group N.V. on 24 May 2017 at 14.00 hours:
Proposal 5a
Proposal to increase the authorized share capital of the Company by 150,000,000 shares to 950,000,000 shares and corporate update.The number of outstanding shares as of 12 April 2017 amounts to 478,986,691 and the current authorized share capital amounts to 800,000,000 shares. The rationale behind the proposed increase of the authorized capital from 800,000,000 shares to 950,000,000 shares is to create sufficient shares
to enable the Company (i) to meet its reserve obligations in respect of the potential numbers of shares which might be required to convert all convertible bonds and warrants including amortization share payments in respect of the Amortizing Bonds due 2018; (ii) to take advantage of new opportunities for
acquisition of additional products, where such new products can be obtained on advantageous terms and (iii) to invest in increasing its own technology and commercialization capabilities to accelerate growth in revenues. Opportunities for (ii) and (iii) above present themselves from time to time and the
Company is exploring a number of such potential positive moves.
The remainder of the un-issued share capital allows the Company to retain a share reserve, as is typical for companies operating in high growth sectors such as biotechnology.